Published in final edited form as:

Cell Calcium. 2020 November 01; 91: 102282. doi:10.1016/j.ceca.2020.102282.

Control by Ca^{2+} of mitochondrial structure and function in pancreatic β -cells

Eleni Georgiadou, Guy A. Rutter*

Section of Cell Biology and Functional Genomics, Department of Metabolism, Digestion and Reproduction, Imperial College London, du Cane Road, London, W12 0NN, UK

Abstract

Mitochondria play a central role in glucose metabolism and the stimulation of insulin secretion from pancreatic β -cells. In this review, we discuss firstly the regulation and roles of mitochondrial Ca^{2+} transport in glucose-regulated insulin secretion, and the molecular machinery involved. Next, we discuss the evidence that mitochondrial dysfunction in β -cells is associated with type 2 diabetes, from a genetic, functional and structural point of view, and then the possibility that these changes may in part be mediated by dysregulation of cytosolic Ca^{2+} . Finally, we review the importance of preserved mitochondrial structure and dynamics for mitochondrial gene expression and their possible relevance to the pathogenesis of type 2 diabetes.

Keywords

Type 2 diabetes; mitochondria; Ca^{2+} ; β -cells; insulin secretion

Abbreviations

$[\text{Ca}^{2+}]_{\text{cyt}}$, $[\text{Ca}^{2+}]_{\text{mt}}$	free cytosolic and intramitochondrial Ca^{2+} respectively
IMM, OMM	inner and outer mitochondrial membrane
(ψ_{m})	mitochondrial membrane potential
(GSIS)	glucose-stimulated insulin secretion
(K_{ATP})	ATP-sensitive potassium channels
(VDCCs)	voltage-dependent-calcium channels
(MCU)	mitochondrial Ca^{2+} uniporter
(mPTP)	mitochondrial permeability transition pore
(NCLX)	mitochondrial $\text{Na}^{+}/\text{Ca}^{2+}$ exchanger

*Address corresponded to Professor Guy Rutter, g.rutter@imperial.ac.uk.

Conflict of Interest

G.A.R. has received grant funding from Sun Pharmaceuticals and from Les Laboratoires Servier, and is a consultant for Sun Pharmaceuticals.

(Mfn1/2)	mitofusin 1/2
(mtDNA)	mitochondrial DNA
(T2D)	type 2 diabetes

1 Introduction

Diabetes now affects more than 450 million people worldwide, a number expected to grow to >700 million by 2045 [1]. Whereas type 1 diabetes (T1D) involves immune-mediated destruction of insulin-secreting pancreatic islet β -cells [2], type 2 diabetes (T2D) involves both impaired insulin secretion and, in most cases, insulin resistance [3]. The pathological changes which occur in the β -cell are still poorly understood but are likely to include alterations to mitochondrial structure and function [4]. Here, we focus on the role of Ca^{2+} regulation of mitochondrial function in both the healthy and the diseased β -cell.

Glucose uptake and metabolism, and a consequent increase in ATP production, are central to the activation of insulin secretion from β -cells as concentrations of the sugar increase in the blood following a meal [5]. Under high glucose concentrations, an increase in cytosolic ATP/ADP ratio leads to the closure of ATP-sensitive potassium (K_{ATP}) channels in the plasma membrane of β -cells. By favouring a net influx of positive charge, K_{ATP} closure promotes plasma membrane depolarization and the opening of the voltage-dependent calcium channels (VDCCs) [6]. The resultant influx of Ca^{2+} then triggers the exocytotic release of insulin-containing secretory granules by activating Ca^{2+} -sensitive granule-resident proteins such as synaptotagmin-7 [7].

Mobilization of intracellular Ca^{2+} from intracellular stores including the endoplasmic reticulum (ER) [8] is important for the potentiation of glucose-stimulated secretion by Gq-coupled metabotropic receptor agonists such as acetyl choline which generate intracellular inositol (1,4,5) *tris* phosphate. Another significant aspect recently described by Klec *et al.* was that under basal glucose conditions, an ER to mitochondrial Ca^{2+} efflux crosstalk was established by the glycogen synthase kinase 3 beta (GSK3 β)-mediated phosphorylation of presenilin-1 [9]. This was reported to enhance mitochondrial responsiveness (increase in respiration and ATP levels) of β -cells [9] during the first phase of elevated glucose conditions and thus, insulin secretion (GSIS) [10]. This has been suggested to be involved in a pre-stimulation of mitochondria that is important for the initial phase of insulin secretion [11]. Finally, although ryanodine receptors are expressed at low levels in β -cells [12] the role of Ca^{2+} -induced Ca^{2+} release [13] in the response to glucose and other secretagogues is still unclear [14]. Nevertheless, acidic Ca^{2+} stores, including endosomes [15] and secretory granules [16] may also generate local Ca^{2+} signals that may be relevant for exocytosis or transfer of Ca^{2+} to other organelles including mitochondria.

“Amplifying” pathways for GSIS [4, 17], further enhance hormone release in the absence of detectable additional increases in cytosolic Ca^{2+} and are thought to contribute to both phases of insulin secretion [18, 19].

Mitochondrial metabolism is central to both signalling pathways (and hence the two phases of glucose-stimulated secretion), as demonstrated by (a) the ability of mitochondrial inhibitors to suppress secretion, (b) the fact that fuel secretagogues which are metabolised largely or exclusively by mitochondria (e.g. leucine, 2-ketoisocaproate) are efficient substances to induce secretion [5, 20] and (c) the association of penetrant mutations in the mitochondrial genome with some forms of diabetes, including maternally-inherited diabetes and deafness (MIDD) [21]. Freidrich's ataxia [22] and the inheritance of common variants in the *TFB1M* gene encoding transcription factor B1 mitochondria [23], are also associated with increased disease risk.

Further emphasising the likely importance of mitochondrial oxidative metabolism for the stimulation of insulin secretion, weak expression in β -cells of both lactate dehydrogenase and the lactate/pyruvate (monocarboxylate) transporter MCT-1 (*Slc16a1*) [24] - both members of the so-called "disallowed" gene group in these cells [25] - means that glycolytically-derived pyruvate is preferentially metabolised by mitochondria [26], ensuring that > 85% of glucose carbon is oxidised fully to CO₂ and H₂O. Supporting the importance of diverting pyruvate towards mitochondrial oxidation, overexpression of lactate dehydrogenase A (LDHA) [27, 28] inhibits secretion in clonal β -cells, though secretion was not affected from rat primary islets [29]. Of note, low levels of LDHA and MCT-1 also ensure that muscle-derived pyruvate and lactate do not cause an inappropriate secretion of insulin during exercise [29, 30]. Nevertheless, these data point towards the critical importance in the control of secretion of both mitochondrial production of ATP, as well as of potential coupling factors involved in the amplification process such as glutamate [31, 32], isocitrate [33] and certain lipid species [34].

1.1 Roles of intramitochondrial Ca²⁺ in the control of insulin secretion

Accumulation of Ca²⁺ by β -cell mitochondria in response to glucose, depolarisation or agonist-induced cytosolic Ca²⁺ increases was first described using recombinant, genetically-encoded and organelle-targeted aequorin (a bioluminescent Ca²⁺ sensor from the jelly fish *Aequoria victoria*) in the mid 1990s [35, 36]. Increased cytosolic Ca²⁺ would naturally impose a drive towards lowered cytosolic ATP levels through increased consumption for ion pumping, granule movement etc. Ca²⁺ transport into mitochondria may also compromise ATP synthesis by lowering the inner mitochondrial membrane (IMM) potential (ψ_m). Indeed, some studies have demonstrated decreased cytosolic (sub-plasma membrane) ATP in response to depolarisation-induced Ca²⁺ influx [37]. However, these ATP-consuming processes are countered, firstly, by the activation of three intramitochondrial Ca²⁺-sensitive dehydrogenases: pyruvate, isocitrate and 2-oxoglutarate dehydrogenases [38]. Activation of mitochondrial ATP synthesis [39] is likely further to complement the enhanced provision of NADH and FADH₂ to the respiratory chain. Finally, activation of the Ca²⁺-stimulated glycerol phosphate dehydrogenase located in the inter-membrane space of mitochondria (and thus regulated by cytosolic Ca²⁺ [40]) is likely also to enhance mitochondrial respiratory chain activity in β -cells [41], where this enzyme is strongly expressed [24]. Stimulation of the malate-aspartate exchange by cytosolic Ca²⁺ may also be involved [42], though the contribution of this process to the control of pyruvate oxidation has only been examined under conditions where the pyruvate dehydrogenase complex is likely to be fully

active, and thus insensitive to further control by Ca^{2+} [43]. The role of this process in β -cells has not been explored yet.

In summary, cytosolic ATP levels (or rather ATP/ADP ratio) are thus likely to reflect the minute-to-minute balance of enhanced mitochondrial oxidation versus enhanced consumption, with Ca^{2+} influencing both processes.

1.2 Regulators of mitochondrial Ca^{2+} transport in pancreatic β -cells

Given the above observations, enhanced mitochondrial Ca^{2+} uptake in pancreatic β -cells might thus provide an innovative and promising strategy to improve insulin secretion in patients with T2D. Accumulation of Ca^{2+} by mitochondria depends on the ψ_m , and is mediated by the mitochondrial Ca^{2+} uniporter (MCU) and its associated regulatory subunits [44–47]. The uniporter complex consists of multiple subunits, namely the regulatory scaffolds MCU Regulator 1 (MCUR1), the Essential MCU Regulator Element (EMRE) and the Ca^{2+} sensors Mitochondrial Calcium Uptake proteins 1, 2 and 3 (MICU1, MICU2 and MICU3) [44, 45, 48–51]. The identification of these components, as well as of the mitochondrial Na^+ - Ca^{2+} exchanger (NCLX) [52] in molecular terms over the last decade has given rise to the possibility that they might provide targets for therapeutics which may modulate insulin secretion.

In 2012, Tarasov *et al.* [47] reported, using simultaneous, multiparametric measurements of Ca^{2+} and ATP/ADP dynamics in the same, patch-clamped single β -cell (Fig. 1 A), the existence of two phases of change in the response to glucose (Fig. 1B). In the first, an initial glucose-induced increase in cytosolic [ATP/ADP] occurred independently of any increase in cytosolic ($[\text{Ca}^{2+}]_{\text{cyt}}$) or of mitochondrial ($[\text{Ca}^{2+}]_{\text{mt}}$) Ca^{2+} concentration. In the second phase, the elevation of $[\text{Ca}^{2+}]_{\text{cyt}}$ resulting from K_{ATP} channel closure led to a gradual increase in $[\text{Ca}^{2+}]_{\text{mt}}$. This, in turn, was likely to activate intramitochondrial dehydrogenases [53] (and perhaps the F1F0 ATP synthase) [54], stimulating respiratory chain activity and hence mitochondrial ATP production (see the description above). Importantly, Ca^{2+} changes in mitochondria were damped with respect to those in cytosol (Fig. 1C) [55], such that low frequency pulses of cytosolic Ca^{2+} resulted in minimal increases in mitochondrial Ca^{2+} , i.e. changes in frequency, as imposed by physiologically glucose, are decoded by mitochondria as modifications in the ATP/ADP increase, providing a further rationale for the existence of kinetically-controlled Ca^{2+} transport systems across the IMM.

We would note that whilst transient increases in $[\text{Ca}^{2+}]_{\text{cyt}}$ can also lead to *decreases* in apparent ATP/ADP ratio when monitored in real time (Fig. 1B), these observations do not exclude the possibility that the extent of the decreases is dampened by the simultaneous stimulation of intramitochondrial dehydrogenases; i.e. the drops would be even larger in the absence of the activation of mitochondrial ATP synthesis.

Moreover, the extent of a Ca^{2+} -induced lowering in cytosolic ATP/ADP may differ between subcellular location - perhaps depending on the number of mitochondria in a given locale - and appeared to be particularly marked when recorded immediately beneath the plasma membrane using total internal reflection of fluorescence microscopy [56]. Nevertheless, our own use of recombinant targeted luciferases [57] demonstrated transient *increases* in

cytosolic ATP in both subcellular regions in responses to depolarisation with KCl, and a more sustained increase in response to high glucose observed for plasma membrane ATP. These apparently contradictory findings emphasise the point that only interventional approaches - in which mitochondrial Ca^{2+} uptake is selectively interrupted by pharmacological or genetic means, or the dehydrogenases rendered Ca^{2+} insensitive - are likely to provide a definitive answer on this point.

Importantly, shRNA-mediated silencing [47] demonstrated that MCU was critical for mitochondrial Ca^{2+} accumulation in primary mouse pancreatic β -cells in response to depolarisation-induced Ca^{2+} increases. Thus, the initial rapid glucose-induced increase in [ATP/ADP] was not affected by MCU silencing whereas the second phase of [ATP/ADP] increase was essentially eliminated. Mitochondrial Ca^{2+} accumulation, catalysed by MCU, was thus revealed in these studies to be essential for the second phase of glucose-induced ATP synthesis by glucose [47] and for insulin secretion as assessed by the release of co-stored Zn^{2+} (Fig. 1 A).

Complementing these findings, Graier and colleagues [58] used a pancreatic β -cell line (INS-1 (832/13) cells) to demonstrate that transient silencing of MICU1 or MCU resulted in impaired mitochondrial Ca^{2+} uptake in response to both Ca^{2+} influx across the plasma membrane and release from the ER, without affecting $[\text{Ca}^{2+}]_{\text{cyt}}$ [58]. Silencing of either protein reduced cytosolic Ca^{2+} oscillations and insulin secretion in response to high glucose.

MICU1 is essential for MCU regulation, binding both MCU and EMRE, and its expression correlates with tissue-dependent differences in mitochondrial Ca^{2+} uptake [48, 59-62]. Additionally, reduced mitochondrial Ca^{2+} sequestration in MICU1- or MCU-silenced cells led to impaired respiration rates, decreased ATP production and reduced GSIS. These findings indicate that the stimulatory effects of Ca^{2+} on metabolism dominate over the inhibitory effect expected from the depolarization that occurs when Ca^{2+} enters through the uniporter [58].

Moreover, recent studies focusing on MICU1 [63, 64] revealed that the latter is essential for proper proteomic organization of the Mitochondrial Contact Site and Cristae Organizing System (MICOS) complex and that its ablation in cultured HEK293T, HeLa cells and mouse embryonic fibroblasts (MEFs) resulted in altered cristae organization and mitochondrial ultrastructure. More precisely, Gottschalk *et al.* demonstrated that cristae junction widening and subsequently dilution of the cristae membrane's proton gradient in MICU1-depleted HeLa cells resulted in IMM depolarisation [64]. Additionally, it was demonstrated that cytochrome *c* re-localised from the cristae into the intermembrane space (IMS) while cristae and matrix $[\text{Ca}^{2+}]$ levels increased as a consequence of cristae junction widening, probably due to the activation of other mitochondrial Ca^{2+} channels. The latter study thus provided the first experimental evidence suggesting that MICU1 has a significant function in contributing to the integrity of the cristae junction and protecting against matrix Ca^{2+} overload, and restriction of cytochrome *c* release to cristae [64].

As noted above, extrusion of Ca^{2+} from the mitochondrial matrix is catalysed chiefly by NCLX. NCLX exchanges one Ca^{2+} ion for three Na^{+} , with the latter balanced in turn by a

Na^+/H^+ exchanger to maintain a polarised ψ_m [52]. Several studies have demonstrated that silencing of NCLX using siRNA in mouse β -cells lead to $[\text{Ca}^{2+}]_{\text{mt}}$ overload with glucose-induced $[\text{Ca}^{2+}]_{\text{cyt}}$ increases, ATP production and the first phase of insulin secretion all strongly impaired [52, 65].

1.3 Inactivation of MCU in mouse β -cells

Even though changes in $[\text{Ca}^{2+}]_{\text{mt}}$ were found to be critical for increases in cytosolic ATP/ADP ratio in the aforementioned *in vitro* studies, it remained unknown whether mitochondrial Ca^{2+} transport may be required for GSIS *in vivo*. Since MCU represents the main route for Ca^{2+} uptake in mitochondria, our group selectively inactivated the uniporter in mouse β -cells to provide a better understanding of its importance in insulin secretion and glucose homeostasis in the living animal [66].

By developing a conditional *Mcu* allele that allowed deletion of all isoforms, and using a highly β -cell-selective *Cre* driver line (INS1 *Cre*) [67], these studies [66] revealed that mitochondrial Ca^{2+} uptake (Fig. 2A-B) was essential for both phases of glucose-stimulated ATP synthesis and insulin secretion in isolated islets from β *Mcu*-null mice (Fig. 2C-D), as well as for the maintenance of normal β -cell mass. Measured in isolated islets, mitochondria within knock-out (KO) β -cells were also more polarised than those in islets from wild-type (WT) animals, suggesting an impaired entrance of positively charged ions (such as Ca^{2+}), necessary for oxidative phosphorylation and ATP production. On the other hand, and despite experiencing larger increases in $[\text{Ca}^{2+}]_{\text{cyt}}$ in response to high glucose in intact KO mouse islets, GSIS was severely inhibited *in vitro* (Fig. 2C-D). These experiments are thus in line with earlier findings in which gene inactivation was achieved *in vitro* and implies important roles for Ca^{2+} -activated mitochondrial oxidative metabolism (i.e. ATP production) and conceivably for the production of coupling molecules such as glutamate, citrate/malate or others.

Extending these findings to the *in vivo* phenotype, β *Mcu*-KO mice showed impaired glucose tolerance 15 min. (Fig. 2E) and insulin secretion 5 min. (Fig. 2F) post-intra-peritoneal glucose injection, while no differences between WT and KO mice were observed at other time points, pointing to the existence of currently undefined compensatory mechanisms. One intriguing possibility could be that in the absence of MCU, mitochondrial NCLX operates in the reverse mode at low ψ_m and allows Ca^{2+} influx. Another observation made during this study was that insulin secretion post-oral glucose gavage was elevated in KO mice at 5 min. This paradoxical result was not due to altered release or action of gut-derived incretins, since islets from KO mice displayed impaired sensitivity to incretin hormones *in vitro*. Measurements of the expression of NCLX, as well as of other genes which may contribute to these apparent compensatory mechanisms, will be required in the future. Nevertheless, these results are in line with previous findings where global *Mcu*-null mice displayed relatively minor phenotypes in cardiac and skeletal muscle function, and no overt glycaemic abnormalities [68, 69].

In conclusion, these findings, which provide only the second description of a conditional tissue-restricted *Mcu*-KO mouse (the first being described in [47]) revealed a critical role for

MCU expression in the control of insulin secretion and the potential for a role in some forms of diabetes.

2 Mitochondrial dynamics

Mitochondria continuously undergo fission and fusion cycles in a dynamic process that is influenced by nutrient supply or demand, as well as by extra- or intracellular factors that are critical to cell survival [70]. As well as influencing mitochondrial turnover (mitochondrial fragmentation is required for mitophagy and hence the replacement of defective mitochondria as shown by Song *et al.* in fission-deficient (increased mitophagy) mouse cardiomyocytes [71]), these dynamics, along with motor-protein-driven mitochondrial translocation by dynein and kinesin family members [14] control the localisation of the organelles vis-à-vis other intracellular organelles and the plasma membrane. These changes may, as a result, control localised changes in Ca^{2+} and ATP generation [57].

Mitochondrial fusion is controlled by the outer mitochondrial membrane dynamin related protein GTPases mitofusin 1 (MFN1) and mitofusin 2 (MFN2) [72], as well as an inner mitochondrial membrane GTPase protein optic atrophy protein 1 (OPA1) [73]. The latter has also been reported to control cristae structure independently of IMM fusion under conditions of low energy substrate availability in MEFs [74]. This process is essential as it involves exchange of proteins, metabolites, and mitochondrial DNA (mtDNA) and thus allows the maintenance of functional mitochondria, which may otherwise have become depolarized by intracellular or extracellular stress [75]. Mitochondrial fission is regulated by the transmembrane protein fission 1 (FIS1) [76], the outer membrane protein mitochondrial fission factor (MFF) [77] and MIEF1/2 (also known as MiD51/49) [78] which are considered as receptors for the recruitment of the GTPase dynamin-related protein 1 (DRP1) to mitochondria from the cytosol [79]. Mitochondrial fission favours the isolation of dysfunctional or damaged mitochondria, which can either be repaired through the fusion cycle or degraded via the mitophagy/autophagy machinery [80]. Alterations of the balance of mitochondrial dynamics, by gain or loss of function of the fission or fusion proteins mentioned above, have been shown to lead to impairments in mitochondrial structure, function or intracellular signalling events in β -cells [75, 81].

2.1 Role of Ca^{2+} in mitochondrial dynamics

It is widely accepted that Ca^{2+} regulates mitochondrial oxidative metabolism [38]. Several studies have demonstrated that there is also a close association between $[\text{Ca}^{2+}]_{\text{mt}}$ and mitochondrial morphology [82–85]. Direct evidence that Ca^{2+} is a critical regulator of mitochondrial dynamics comes from the fact that mitochondrial Ca^{2+} overload, triggering mitochondrial permeability transition pore (mPTP) opening [86], can lead to mitochondrial fragmentation whereas mitochondrial Ca^{2+} depletion results in mitochondrial hyperfusion in a number of cell types [87].

In non-pancreatic cells, such as cardiomyocytes and hepatocytes, increases in $[\text{Ca}^{2+}]_{\text{cyt}}$ promote the translocation of DRP1 to mitochondria and induce mitochondrial fission [88, 89]. In addition, mitochondrial Ca^{2+} overload through voltage-dependent anion channels (VDACs) and MCU can stimulate rapid mitochondrial fission by activating DRP1 in

cultured neuronal cells [90]. On the other hand, muscle fibres in *Drip1* KO mice show increased expression of MCU, mitochondrial Ca^{2+} overload, opening of mPTP, mitochondrial swelling and ultimately, myofiber weakness or death [91, 92]. Lablanche S. *et al.*, demonstrated that the Ca^{2+} -dependent mPTP opening in INS-1 cells led to cell death under high levels of glucose or fructose but did not investigate mitochondrial structure changes [93]. Hence, the potential role of these processes in controlling mitochondrial structure in pancreatic β -cells, and its role in diabetes aetiology, remains poorly explored.

Intracellular mitochondrial motility is another pathway regulated by Ca^{2+} and allows appropriate distribution of organelles for local ATP supply and Ca^{2+} buffering near perinuclear or cytoplasmic membrane clusters [94]. Thus, Ca^{2+} binds to the mitochondria-associated Rho GTPase (Miro) through a pair of EF-hand Ca^{2+} -binding motifs on the OMM complex and regulates Ca^{2+} -dependent mitochondrial motility [95]. For example, motility of astrocytic mitochondria is dependent on intracellular Ca^{2+} concentrations since elevated $[\text{Ca}^{2+}]$ immobilizes astrocytic mitochondria, whereas low $[\text{Ca}^{2+}]$ under resting conditions causes mitochondria to be highly mobile [96]. Similar behaviour is observed in neurons [97].

Finally, participation by Ca^{2+} in the control of mitochondrial dynamics may also include mitophagy, a highly specialized process that removes dysfunctional mitochondria [98]. This has been observed in mammalian cells and animal models where Ca^{2+} dysregulation and reactive oxygen species (ROS) production are potential mitophagy inducers [99, 100]. More details on the role of mitophagy and its control by Ca^{2+} can be found in [94, 100].

2.2 Ca^{2+} regulation of mitochondrial dynamics in β -cells

Abnormalities in mitochondrial morphology, function and dynamics are observed in diabetic rat models [101, 102], β -cell-derived lines [103], as well as in islets isolated from people with T2D. Whether and how defects in Ca^{2+} homeostasis, known to occur in the β -cell in diabetes [104] contribute to these structural changes, is presently unclear and is an important area for exploration.

β -cells from patients with T2D and both diabetic Goto Kakizaki (GK) and Zucker Diabetic Fatty (ZDF) rats develop mitochondrial fragmentation suggesting an impairment of mitochondrial dynamics under high circulating glucose conditions [70, 101]. Molina *et al.* [75] demonstrated that mice β -cells treated with free fatty acids (FFAs) - circulating levels of which are increased in T2D - displayed dramatic and rapid mitochondrial fragmentation. The authors associated this observation with defective mitochondrial fusion since MFN2 expression levels decreased. Men *et al.*, on the other hand, noted that the increased mitochondrial fission observed under conditions of glucotoxicity in GK rats was linked to increased expression of DRP1 in β -cells [105]. Nevertheless, the role of mitochondrial fragmentation in β -cells under high nutrient conditions remains unclear.

Defects in mitochondrial ultrastructure, including swelling and altered cristae structure, were observed in diabetic rat models [101] and were associated with reduced insulin secretion, lower ATP/ADP ratio and depolarisation of the IMM (i.e. impaired ability to sustain highly negatively charged membrane potential) [106]. Mitochondrial volume density was also

significantly increased in comparison with WT animals, and ψ_m was more positive in diabetic versus normoglycemic rats. Hence, a possible explanation could be that mitochondrial Ca^{2+} overload followed by opening of the mPTP [107] are linked to mitochondrial impairment, insulin secretory failure and, ultimately, hyperglycaemia [108].

Are these changes in structure functionally relevant? Recent results from Ku and colleagues [109], and ourselves [110] have sought to answer this question by imposing forced changes in the expression of key regulators of mitochondrial fission or fusion and demonstrate that the balance between these processes is critical for normal β -cell fuel sensing. Deletion or silencing of one or more of these factors (e.g. *Drp1* or *Mfn1* plus *Mfn2*) [109–111] exerted profound effects on insulin secretion and glucose homeostasis in mice, despite opposing effects on mitochondrial fragmentation. Thus, deletion of *Drp1* led to aggregation of mitochondria near the nucleus and inhomogeneity in glucose-induced NAD(P)H increases across the cell versus WT controls [109]. Although overall O_2 consumption was normal, the period of cytosolic Ca^{2+} oscillations was increased in *Drp1* KO islets, demonstrating a requirement for mitochondrial localisation and/or fragmentation or normal responses: of note the expression of a number of mitochondria-associated genes was decreased (e.g. *Ndufb8*, *Sdhb*, *Mtco1* or ETC complexes I, II and IV respectively) [109]. Lastly, since glucose-unresponsive cells (INS1-832/2) exhibit poorer mitochondrial dynamics than glucose-responsive cells (INS1-832/13), Schultz *et al.* decided to investigate mitochondrial morphology by overexpressing *Fis1* in glucose-unresponsive cells and demonstrated that increased fission could restore GSIS [112].

On the other hand, deletion of *Opa1* in β -cells, resulted in respiratory chain defects and impaired insulin secretion [81]. Our own study [110], of the effects of combined *Mfn1* and *Mfn2* inactivation revealed that simultaneous ablation of both mitofusins selectively in β -cells in adult mice had catastrophic effects on β -cell function, prompting sharp reductions in glucose-induced cytosolic and mitochondrial Ca^{2+} increases and impaired insulin secretion both *in vivo* and *in vitro*. Mitochondrial membrane potential was highly depolarised and β -cell mass was significantly reduced in β *Mfn1/2* KO animals demonstrating the importance of maintained mitochondrial ultrastructure for β -cell survival. Nonetheless, the role and regulation of mitochondrial fission and fusion factors in the β -cell in diabetes mellitus still remain to be fully elucidated. For instance, whether and how β *Mfn1/2* KO influences ER-mitochondria contacts in β -cells remains unknown to date. MFN2 is currently under debate in regard to its interaction and function with the ER. Scorrano and colleagues propose that MFN2 is an ER-mitochondria tether whose ablation in MEFs decreases inter-organellar juxtaposition and communication [113]. In contrast, Pizzo *et al.* demonstrate that MFN2 operates as a distance keeper to prevent excessive, potentially toxic, proximity between the two organelles in MEFs [114, 115].

An interesting recent report from Montemurro C. *et al.* [116] revealed changes in mitochondrial structure and function, coincident with cytosolic and mitochondrial Ca^{2+} at different stages of the cell cycle (Fig. 3). Thus, in the INS1 (832/13) insulinoma line, fragmented mitochondria and phosphorylated DRP1 were observed in S and G2/M phases of the cell cycle during which DNA/lipid synthesis and mitosis occur and was associated with increase basal O_2 consumption rates. A rise in cytosolic (and reduction in mitochondrial)

Ca^{2+} uptake was observed at G1/S and was consistent with the requirement for Ca^{2+} to initiate centrosome duplication at early G1/S. On the other hand, intramitochondrial Ca^{2+} was elevated in G2/M, providing a possible explanation for increased respiration (through activation of mitochondrial Ca^{2+} -dependent dehydrogenases of the tricarboxylic acid (TCA) cycle). Taken together, this study confirmed the link between mitochondrial network and Ca^{2+} compartmentalization as β -cells transition through cell cycle.

3 mtDNA mutations and diabetes

mtDNA integrity and stability are necessary for normal β -cell function and may play crucial roles in the development of hyperglycemia [117]. Among the most convincing links between mitochondrial dysfunction and diabetes are mtDNA mutations which occur either as single deletions, which usually manifest as *de novo* mutations, or multiple mtDNA deletions, which occur somatically and accumulate with age (Fig. 4). Both forms can result in mitochondrial respiratory chain deficiency and disease [118]. For example, in Kearns-Sayre syndrome (KSS), which is associated with a single deletion myopathy, patients can develop impaired GSIS, reduced β -cell mass, and dysmorphic islet architecture [119]. Another example is the A3243G mutation in mitochondrial tRNA-Leu, which also causes mitochondrial encephalomyelopathy and lactic acidosis [21], and is associated with MIDD. Sufferers of MIDD show reduction in β -cell mass and subsequent insulin deficiency without reduced insulin sensitivity in peripheral tissues [117]. Hence, MIDD mutations were among the first evidence of a role for energetic failure in GSIS.

Mitochondrial function in the β -cell can also be modulated by the extent of mitochondrial gene transcription. Stability, transcriptional activity and copy number of mtDNA is predominantly controlled by a nuclear-encoded factor, the mitochondrial transcription factor A (TFAM) and the mitochondrial transcription factor B2 (TFB2M) [120, 121]. Wiederkehr *et al.*, demonstrated that suppression of the transcription factor pancreatic duodenum homeobox-1 (PDX1), required for the expression of insulin in mouse islets, decreased TFAM expression which coincided with hyperglycaemia, attenuation of mitochondrial signals and failure to raise cytosolic ATP levels [120]. These results confirmed that TFAM was a direct target of PDX1 and implicate TFAM in the preservation of mitochondrial function [120]. On the other hand, TFAM overexpression in *Pdx1* deficient (*Pdxt*^{-/-}) mice restored both glucose-dependent ATP synthesis and insulin secretion by increasing the expression of mtDNA-encoded genes. Additionally, the authors were able to restore the mitochondrial Ca^{2+} signal in *Pdxt*^{-/-} islets using a mitochondrial $\text{Na}^+/\text{Ca}^{2+}$ exchanger inhibitor which resulted in improved ATP production and insulin secretion [122]. These findings thus demonstrate that an increase in $[\text{Ca}^{2+}]_{\text{mt}}$ can compensate for reduced levels of mtDNA encoded respiratory chain complex subunits.

While the role of TFAM in pancreatic β -cells has been well characterised, it is only recently that the significance of TFB2M in mitochondrial and cellular function of pancreatic β -cells has been elucidated. β -cell-specific knockout of *Tfb2m* in a mouse model, as well as in INS1 832/13 cells [123], resulted in decreased expression of mitochondrial-encoded genes and lowered mtDNA content. This led to severe mitochondrial dysfunction, characterised by diminished hyperpolarisation of the IMM, impaired O_2 consumption and reduced ATP

production. Nicholas *et al.*, also observed increased level of autophagy and mitophagy suggesting an unforeseen critical role for this mitochondrial transcription factor [123].

Mitochondrial transcription factor B1 (TFB1M) on the other hand, is believed to not be an authentic transcription factor. In fact, it functions as a methyl transferase which, if lost, leads to ribosome destabilization and an abrogation of protein synthesis. Koeck *et al.* identified a common variant in the human *TFB1M* gene [124] associated with reduced insulin secretion, elevated postprandial glucose levels and future risk of T2D in female patients. Carriers of the risk allele also exhibited decreased complex I activity and protein level in pancreatic islets [124]. Similarly, heterozygous *Tfb1m* expression in mouse models induced lower levels of TFB1M in islets, impaired mitochondrial function and lower GSIS *in vivo* and *in vitro* [124]. Moreover, silencing of TFB1M in clonal insulin-secreting cells impaired complexes of the mitochondrial OXPHOS system leading to impaired ATP synthesis and GSIS while ROS levels in response to cellular stress increased. These authors also found signs of apoptosis and necrosis in *Tfb1m*^{-/-} islets which may also be relevant for human T2D, where (some) β -cell loss and apoptosis in islets have been reported [125]. Hence, these findings demonstrated that *Tfb1m* deficiency in β -cells can induce mitochondrial dysfunction and subsequently diabetes owing to combined loss of β -cell function and mass (Fig. 4). The effects of these changes on cytosolic or mitochondrial Ca^{2+} are, however, presently undefined.

Lastly, normal mitochondrial dynamics are essential to control mitochondrial content mixing and the maintenance of mtDNA. Thus, and for as yet unknown reasons, severe impairment of mitochondrial fusion drastically affects mtDNA copy number, in pancreatic and extra-pancreatic cells. For example, mtDNA copy number in mouse β -cells lacking *Opa1* is unchanged, but the activity of complex IV is significantly decreased, perturbing glucose-stimulated ATP production and GSIS [81]. Conversely, Silva Ramos *et al.* demonstrated that loss of OMM, but not IMM fusion, lead to nucleoid clustering in mouse cardiomyocytes [126]. Assessment of mitochondrial transcription in tissue homogenates revealed that abolition of OMM fusion did not affect transcription or mutagenesis of mtDNA but instead, mitochondrial fusion was necessary to maintain the stoichiometry of the protein components of the mtDNA replisome in cardiac cells [126]. Whether mitochondrial fusion is similarly important in β -cells remains to be explored.

4 Conclusions and perspectives

Mitochondria represent the targets for fluctuations in intracellular Ca^{2+} in β -cells, with the ions acting both within the mitochondrial matrix (on oxidative metabolism) and on targets on the mitochondrial intermembrane space or the outer membrane (translocation, fission). Abnormal Ca^{2+} dynamics in the diseased β -cell, including both elevated basal Ca^{2+} and impaired increases in response to high glucose, may thus contribute to altered mitochondrial function, stability and structure, leading to a vicious circle in which these changes further impair stimulus-secretion coupling and β -cell viability. Whether they also impact the β -cell in the context of T1D, for example by affecting ER stress pathways or antigen presentation, is unknown. Nonetheless, therapeutics which mitigate or suppress these alterations, for

example by activating MCU [127], may have utility for the treatment of some forms of diabetes.

Acknowledgements

G.A.R. was supported by a Wellcome Trust Investigator Award (212625/Z/18/Z), and by an MRC Programme grant (MR/R022259/1). This project has received funding from the European Union's Horizon 2020 research and innovation programme via the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115881 (RHAPSODY). This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA. We thank Drs Tristan Rodriguez and Ana Lima for useful discussion.

References

1. International, DF. [cited 2020 29/6/20] About Diabetes. 9th Edition 2020. [Available from: <https://www.idf.org/aboutdiabetes/what-is-diabetes/facts-figures.html>]
2. Atkinson MA, Eisenbarth GS, Michels AW. Type 1 diabetes. Lancet. 2014; 383(9911):69–82. [PubMed: 23890997]
3. Kahn SE, Cooper ME, Del Prato S. Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. Lancet. 2014; 383(9922):1068–83. [PubMed: 24315620]
4. Rutter GAGE, Martinez-Sanchez A, Pullen TJ. Metabolic and functional specialisations of the pancreatic beta cell: gene disallowance, mitochondrial metabolism and intercellular connectivity. Diabetologia. 2020
5. Rutter GA, et al. Pancreatic beta-cell identity, glucose sensing and the control of insulin secretion. Biochem J. 2015; 466(2):203–18. [PubMed: 25697093]
6. Rorsman P, Ashcroft FM. Pancreatic β -Cell Electrical Activity and Insulin Secretion: Of Mice and Men. Physiol Rev. 2018; 98(1):117–214. [PubMed: 29212789]
7. Gauthier BR, Wollheim CB. Synaptotagmins bind calcium to release insulin. Am J Physiol Endocrinol Metab. 2008; 295(6):E1279–86. [PubMed: 18713958]
8. Prentki M, Wollheim CB. Cytosolic free Ca^{2+} in insulin secreting cells and its regulation by isolated organelles. Experientia. 1984; 40(10):1052–60. [PubMed: 6436050]
9. Klec C, et al. Glycogen Synthase Kinase 3 β Controls Presenilin-1-Mediated Endoplasmic Reticulum Ca^{2+} Leak Directed to Mitochondria in Pancreatic Islets and β -Cells. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology. 2019; 52(1):57–75.
10. Klec C, et al. Presenilin-1 Established ER- Ca^{2+} Leak: a Follow Up on Its Importance for the Initial Insulin Secretion in Pancreatic Islets and β -Cells upon Elevated Glucose. Cell Physiol Biochem. 2019; 53(3):573–586. [PubMed: 31529929]
11. Klec C, et al. Calcium Signaling in β -cell Physiology and Pathology: A Revisit. International journal of molecular sciences. 2019; 20(24):6110.
12. Islam MS, et al. In situ activation of the type 2 ryanodine receptor in pancreatic beta cells requires cAMP-dependent phosphorylation. Proc Natl Acad Sci U S A. 1998; 95(11):6145–50. [PubMed: 9600932]
13. Lemmens R, et al. Ca^{2+} -induced Ca^{2+} release from the endoplasmic reticulum amplifies the Ca^{2+} signal mediated by activation of voltage-gated L-type Ca^{2+} channels in pancreatic beta-cells. J Biol Chem. 2001; 276(13):9971–7. [PubMed: 11139580]
14. Varadi A, Rutter GA. Ca^{2+} -induced Ca^{2+} release in pancreatic islet beta-cells: critical evaluation of the use of endoplasmic reticulum-targeted "cameleons". Endocrinology. 2004; 145(10):4540–9. [PubMed: 15217981]
15. Arredouani A, et al. Nicotinic Acid Adenine Dinucleotide Phosphate (NAADP) and Endolysosomal Two-pore Channels Modulate Membrane Excitability and Stimulus-Secretion Coupling in Mouse Pancreatic β Cells. J Biol Chem. 2015; 290(35):21376–92. [PubMed: 26152717]

16. Mitchell KJ, Lai FA, Rutter GA. Ryanodine receptor type I and nicotinic acid adenine dinucleotide phosphate receptors mediate Ca^{2+} release from insulin-containing vesicles in living pancreatic beta-cells (MIN6). *J Biol Chem.* 2003; 278(13):11057–64. [PubMed: 12538591]
17. Henquin JC. The dual control of insulin secretion by glucose involves triggering and amplifying pathways in β -cells. *Diabetes Res Clin Pract.* 2011; 93(1):S27–31. [PubMed: 21864748]
18. Simpson RG, et al. Early phase of insulin release. *Diabetes.* 1968; 17(11):684–92. [PubMed: 5687345]
19. Mourad NI, Nenquin M, Henquin J-C. Metabolic amplifying pathway increases both phases of insulin secretion independently of β -cell actin microfilaments. *American Journal of Physiology-Cell Physiology.* 2010; 299(2):C389–C398. [PubMed: 20484655]
20. Maechler P, Wollheim CB. Mitochondrial signals in glucose-stimulated insulin secretion in the beta cell. *J Physiol.* 2000; 529 Pt 1(Pt 1):49–56. [PubMed: 11080250]
21. van den Ouweland JM, et al. Functional and morphological abnormalities of mitochondria harbouring the tRNA(Leu)(UUR) mutation in mitochondrial DNA derived from patients with maternally inherited diabetes and deafness (MIDD) and progressive kidney disease. *Diabetologia.* 1999; 42(4):485–92. [PubMed: 10230654]
22. Cnop M, et al. Central role and mechanisms of β -cell dysfunction and death in friedreich ataxia-associated diabetes. *Ann Neurol.* 2012; 72(6):971–82. [PubMed: 23280845]
23. Koeck T, et al. A common variant in TFB1M is associated with reduced insulin secretion and increased future risk of type 2 diabetes. *Cell Metab.* 2011; 13(1):80–91. [PubMed: 21195351]
24. Sekine N, et al. Low Lactate Dehydrogenase and High Mitochondrial Glycerol Phosphate Dehydrogenase in Pancreatic Beta-Cells. Potential Role in Nutrient Sensing. *Journal of Biological Chemistry.* 1994; 269:4895–4902.
25. Pullen TJ, Huising MO, Rutter GA. Analysis of Purified Pancreatic Islet Beta and Alpha Cell Transcriptomes Reveals 11 β -Hydroxysteroid Dehydrogenase (Hsd11b1) as a Novel Disallowed Gene. *Frontiers in Genetics.* 2017; 8(41)
26. Schuit F, et al. Metabolic fate of glucose in purified islet cells. Glucose-regulated anaplerosis in beta cells. *J Biol Chem.* 1997; 272(30):18572–9. [PubMed: 9228023]
27. Zhao C, Rutter GA. Overexpression of lactate dehydrogenase A attenuates glucose-induced insulin secretion in stable MIN-6 beta-cell lines. *FEBS Lett.* 1998; 430(3):213–6. [PubMed: 9688541]
28. Ainscow EK, Zhao C, Rutter GA. Acute overexpression of lactate dehydrogenase-A perturbs beta-cell mitochondrial metabolism and insulin secretion. *Diabetes.* 2000; 49(7):1149–55. [PubMed: 10909972]
29. Ishihara H, et al. Overexpression of monocarboxylate transporter and lactate dehydrogenase alters insulin secretory responses to pyruvate and lactate in beta cells. *J Clin Invest.* 1999; 104(11):1621–9. [PubMed: 10587526]
30. Pullen TJ, et al. Overexpression of monocarboxylate transporter-1 (SLC16A1) in mouse pancreatic β -cells leads to relative hyperinsulinism during exercise. *Diabetes.* 2012; 61(7):1719–25. [PubMed: 22522610]
31. Maechler P, Wollheim CB. Mitochondrial function in normal and diabetic beta-cells. *Nature.* 2001; 414(6865):807–12. [PubMed: 11742413]
32. Ghenni G, et al. Glutamate acts as a key signal linking glucose metabolism to incretin/cAMP action to amplify insulin secretion. *Cell Rep.* 2014; 9(2):661–73. [PubMed: 25373904]
33. Ferdaoussi M, et al. Isocitrate-to-SEN1 signaling amplifies insulin secretion and rescues dysfunctional β cells. *J Clin Invest.* 2015; 125(10):3847–60. [PubMed: 26389676]
34. Prentki M, Matschinsky FM, Madiraju SR. Metabolic signaling in fuel-induced insulin secretion. *Cell Metab.* 2013; 18(2):162–85. [PubMed: 23791483]
35. Rutter GA, et al. Stimulated Ca^{2+} influx raises mitochondrial free Ca^{2+} to supramicromolar levels in a pancreatic beta-cell line. Possible role in glucose and agonist-induced insulin secretion. *J Biol Chem.* 1993; 268(30):22385–90. [PubMed: 8226749]
36. Kennedy ED, et al. Glucose-stimulated insulin secretion correlates with changes in mitochondrial and cytosolic Ca^{2+} in aequorin-expressing INS-1 cells. *The Journal of clinical investigation.* 1996; 98(11):2524–2538. [PubMed: 8958215]

37. Li J, et al. Oscillations of sub-membrane ATP in glucose-stimulated beta cells depend on negative feedback from Ca(2+). *Diabetologia*. 2013; 56(7):1577–86. [PubMed: 23536115]
38. Denton RM, McCormack JG. On the role of the calcium transport cycle in heart and other mammalian mitochondria. *FEBS Lett*. 1980; 119(1):1–8.
39. De Marchi U, et al. Calcium co-regulates oxidative metabolism and ATP synthase-dependent respiration in pancreatic beta cells. *J Biol Chem*. 2014; 289(13):9182–94. [PubMed: 24554722]
40. Hansford RG, Chappell JB. The effect of Ca²⁺ on the oxidation of glycerol phosphate by blowfly flight-muscle mitochondria. *Biochem Biophys Res Commun*. 1967; 27(6):686–92. [PubMed: 4964598]
41. Rutter GA, Pralong WF, Wollheim CB. Regulation of mitochondrial glycerol-phosphate dehydrogenase by Ca²⁺ within electroporabilized insulin-secreting cells (INS-1). *Biochim Biophys Acta*. 1992; 1175(1):107–13. [PubMed: 1482691]
42. Szibor M, et al. Cytosolic, but not matrix, calcium is essential for adjustment of mitochondrial pyruvate supply. *J Biol Chem*. 2020; 295(14):4383–4397. [PubMed: 32094224]
43. Rutter GA, McCormack JG, Halestrap AP, Denton RM. The roles of cytosolic and intramitochondrial Ca²⁺ and the mitochondrial Ca²⁺-uniporter (MCU) in the stimulation of mammalian oxidative phosphorylation. *Journal of Biological Chemistry*. 2020
44. Baughman JM, et al. Integrative genomics identifies MCU as an essential component of the mitochondrial calcium uniporter. *Nature*. 2011; 476(7360):341–5. [PubMed: 21685886]
45. De Stefani D, et al. A forty-kilodalton protein of the inner membrane is the mitochondrial calcium uniporter. *Nature*. 2011; 476(7360):336–40. [PubMed: 21685888]
46. Kirichok Y, Krapivinsky G, Clapham DE. The mitochondrial calcium uniporter is a highly selective ion channel. *Nature*. 2004; 427(6972):360–4. [PubMed: 14737170]
47. Tarasov AI, et al. The mitochondrial Ca²⁺ uniporter MCU is essential for glucose-induced ATP increases in pancreatic beta-cells. *PLoS One*. 2012; 7(7)
48. Mallilankaraman K, et al. MICU1 is an essential gatekeeper for MCU-mediated mitochondrial Ca(2+) uptake that regulates cell survival. *Cell*. 2012; 151(3):630–44. [PubMed: 23101630]
49. Plovanich M, et al. MICU2, a paralog of MICU1, resides within the mitochondrial uniporter complex to regulate calcium handling. *PLoS One*. 2013; 8(2)
50. Sancak Y, et al. EMRE is an essential component of the mitochondrial calcium uniporter complex. *Science*. 2013; 342(6164):1379–82. [PubMed: 24231807]
51. Tomar D, et al. MCUR1 Is a Scaffold Factor for the MCU Complex Function and Promotes Mitochondrial Bioenergetics. *Cell Rep*. 2016; 15(8):1673–85. [PubMed: 27184846]
52. Palty, R; , et al. NCLX is an essential component of mitochondrial Na⁺/Ca²⁺ exchange. *Proc Natl Acad Sci U S A*; 2010. 436–41.
53. McCormack JG, Halestrap AP, Denton RM. Role of calcium ions in regulation of mammalian intramitochondrial metabolism. *Physiol Rev*. 1990; 70(2):391–425. [PubMed: 2157230]
54. Harris DA, Das AM. Control of mitochondrial ATP synthesis in the heart. *Biochem J*. 1991; 280(Pt 3):561–73. [PubMed: 1837214]
55. Tarasov AI, et al. Frequency-dependent mitochondrial Ca(2+) accumulation regulates ATP synthesis in pancreatic β cells. *Pflugers Archiv : European journal of physiology*. 2013; 465(4):543–554. [PubMed: 23149488]
56. Li J, et al. Oscillations of sub-membrane ATP in glucose-stimulated beta cells depend on negative feedback from Ca(2+). *Diabetologia*. 2013; 56(7):1577–1586. [PubMed: 23536115]
57. Kennedy HJ, et al. Glucose generates sub-plasma membrane ATP microdomains in single islet beta-cells. Potential role for strategically located mitochondria. *J Biol Chem*. 1999; 274(19):13281–91. [PubMed: 10224088]
58. Alam MR, et al. Mitochondrial Ca²⁺ uptake 1 (MICU1) and mitochondrial ca²⁺ uniporter (MCU) contribute to metabolism-secretion coupling in clonal pancreatic β -cells. *J Biol Chem*. 2012; 287(41):34445–54. [PubMed: 22904319]
59. Xing Y, et al. Dimerization of MICU Proteins Controls Ca(2+) Influx through the Mitochondrial Ca(2+) Uniporter. *Cell Rep*. 2019; 26(5):1203–1212.e4. [PubMed: 30699349]

60. Phillips CB, Tsai CW, Tsai MF. The conserved aspartate ring of MCU mediates MICU1 binding and regulation in the mitochondrial calcium uniporter complex. *Elife*. 2019; 8
61. Csordás G, et al. MICU1 controls both the threshold and cooperative activation of the mitochondrial Ca^{2+} uniporter. *Cell metabolism*. 2013; 17(6):976–987. [PubMed: 23747253]
62. Fan M, et al. Structure and mechanism of the mitochondrial Ca^{2+} uniporter holocomplex. *Nature*. 2020; 582(7810):129–133. [PubMed: 32494073]
63. Tomar D, et al. MICU1 regulates mitochondrial cristae structure and function independent of the mitochondrial calcium uniporter channel. *bioRxiv*. 2019
64. Gottschalk B, et al. MICU1 controls cristae junction and spatially anchors mitochondrial Ca^{2+} uniporter complex. *Nature Communications*. 2019; 10(1):3732.
65. Nita II, et al. The mitochondrial $\text{Na}^{+}/\text{Ca}^{2+}$ exchanger upregulates glucose dependent Ca^{2+} signalling linked to insulin secretion. *PLoS One*. 2012; 7(10)
66. Georgiadou E, et al. The pore-forming subunit MCU of the mitochondrial Ca^{2+} uniporter is required for normal glucose-stimulated insulin secretion in vitro and in vivo in mice. *Diabetologia*. 2020
67. Thorens B, et al. *Ins1(Cre)* knock-in mice for beta cell-specific gene recombination. *Diabetologia*. 2015; 58(3):558–565. [PubMed: 25500700]
68. Pan X, et al. The physiological role of mitochondrial calcium revealed by mice lacking the mitochondrial calcium uniporter. *Nature Cell Biology*. 2013; 15(12):1464–1472. [PubMed: 24212091]
69. Harrington JL, Murphy E. The mitochondrial calcium uniporter: mice can live and die without it. *J Mol Cell Cardiol*. 2015; 78:46–53. [PubMed: 25451167]
70. Dlaskova A, et al. 4Pi microscopy reveals an impaired three-dimensional mitochondrial network of pancreatic islet beta-cells, an experimental model of type-2 diabetes. *Biochim Biophys Acta*. 2010; 1797(6-7):1327–41. [PubMed: 20144584]
71. Song M, et al. Abrogating Mitochondrial Dynamics in Mouse Hearts Accelerates Mitochondrial Senescence. *Cell Metab*. 2017; 26(6):872–883.e5. [PubMed: 29107503]
72. Santel A, Fuller MT. Control of mitochondrial morphology by a human mitofusin. *J Cell Sci*. 2001; 114(5):867–74. [PubMed: 11181170]
73. Misaka T, Miyashita T, Kubo Y. Primary structure of a dynamin-related mouse mitochondrial GTPase and its distribution in brain, subcellular localization, and effect on mitochondrial morphology. *J Biol Chem*. 2002; 277(18):15834–42. [PubMed: 11847212]
74. Patten DA, et al. OPA1-dependent cristae modulation is essential for cellular adaptation to metabolic demand. *Embo j*. 2014; 33(22):2676–91. [PubMed: 25298396]
75. Molina AJ, et al. Mitochondrial networking protects beta-cells from nutrient-induced apoptosis. *Diabetes*. 2009; 58(10):2303–15. [PubMed: 19581419]
76. James DI, et al. hFis1, a novel component of the mammalian mitochondrial fission machinery. *J Biol Chem*. 2003; 278(38):36373–9. [PubMed: 12783892]
77. Gandre-Babbe S, van der Bliek AM. The novel tail-anchored membrane protein Mff controls mitochondrial and peroxisomal fission in mammalian cells. *Mol Biol Cell*. 2008; 19(6):2402–12. [PubMed: 18353969]
78. Yu R, et al. MIEF1/2 function as adaptors to recruit Drp1 to mitochondria and regulate the association of Drp1 with Mff. *Scientific Reports*. 2017; 7(1):880. [PubMed: 28408736]
79. Yoon Y, et al. The mitochondrial protein hFis1 regulates mitochondrial fission in mammalian cells through an interaction with the dynamin-like protein DLP1. *Mol Cell Biol*. 2003; 23(15):5409–20. [PubMed: 12861026]
80. van der Bliek AM, Shen Q, Kawajiri S. Mechanisms of mitochondrial fission and fusion. *Cold Spring Harb Perspect Biol*. 2013; 5(6)
81. Zhang Z, et al. The dynamin-related GTPase Opa1 is required for glucose-stimulated ATP production in pancreatic beta cells. *Mol Biol Cell*. 2011; 22(13):2235–45. [PubMed: 21551073]
82. Bianchi K, et al. Calcium and mitochondria: mechanisms and functions of a troubled relationship. *Biochimica et Biophysica Acta (BBA) - Molecular Cell Research*. 2004; 1742(1):119–131. [PubMed: 15590062]

83. Szabadkai G, et al. Drp-1-Dependent Division of the Mitochondrial Network Blocks Intraorganellar Ca²⁺ Waves and Protects against Ca²⁺-Mediated Apoptosis. *Molecular Cell*. 2004; 16(1):59–68. [PubMed: 15469822]
84. Frieden M, et al. Ca²⁺ Homeostasis during Mitochondrial Fragmentation and Perinuclear Clustering Induced by hFis1. *Journal of Biological Chemistry*. 2004; 279(21):22704–22714.
85. Breckenridge DG, et al. Caspase cleavage product of BAP31 induces mitochondrial fission through endoplasmic reticulum calcium signals, enhancing cytochrome c release to the cytosol. *Journal of Cell Biology*. 2003; 160(7):1115–1127.
86. Contreras L, et al. Mitochondria: The calcium connection. *Biochimica et Biophysica Acta (BBA) - Bioenergetics*. 2010; 1797(6):607–618. [PubMed: 20470749]
87. Brookes PS, et al. Calcium, ATP, and ROS: a mitochondrial love-hate triangle. *American Journal of Physiology-Cell Physiology*. 2004; 287(4):C817–C833. [PubMed: 15355853]
88. Xu S, et al. Cadmium induced Drp1-dependent mitochondrial fragmentation by disturbing calcium homeostasis in its hepatotoxicity. *Cell Death Dis*. 2013; 4(3):e540. [PubMed: 23492771]
89. Pennanen C, et al. Mitochondrial fission is required for cardiomyocyte hypertrophy mediated by a Ca²⁺-calcineurin signaling pathway. *J Cell Sci*. 2014; 127
90. Han XJ, et al. CaM kinase I alpha-induced phosphorylation of Drp1 regulates mitochondrial morphology. *J Cell Biol*. 2008; 182(3):573–85. [PubMed: 18695047]
91. Giorgio V, et al. Calcium and regulation of the mitochondrial permeability transition. *Cell Calcium*. 2018; 70:56–63. [PubMed: 28522037]
92. Favaro G, et al. DRP1-mediated mitochondrial shape controls calcium homeostasis and muscle mass. *Nature Communications*. 2019; 10(1):2576.
93. Lablanche S, et al. Protection of pancreatic INS-1 β -cells from glucose- and fructose-induced cell death by inhibiting mitochondrial permeability transition with cyclosporin A or metformin. *Cell death & disease*. 2011; 2(3):e134–e134. [PubMed: 21430707]
94. Romero-Garcia S, Prado-Garcia H. Mitochondrial calcium: Transport and modulation of cellular processes in homeostasis and cancer (Review). *Int J Oncol*. 2019; 54(4):1155–1167. [PubMed: 30720054]
95. Wang X, Schwarz TL. The mechanism of Ca²⁺ -dependent regulation of kinesin-mediated mitochondrial motility. *Cell*. 2009; 136(1):163–74. [PubMed: 19135897]
96. Kremneva E, et al. Motility of astrocytic mitochondria is arrested by Ca²⁺-dependent interaction between mitochondria and actin filaments. *Cell Calcium*. 2013; 53(2):85–93. [PubMed: 23177663]
97. Saotome, M; , et al. Bidirectional Ca²⁺-dependent control of mitochondrial dynamics by the Miro GTPase. *Proc Natl Acad Sci U S A*; 2008. 20728–33.
98. Soleimanpour SA, et al. Diabetes Susceptibility Genes Pdx1 and Clec16a Function in a Pathway Regulating Mitophagy in β -Cells. *Diabetes*. 2015; 64(10):3475–3484. [PubMed: 26085571]
99. Gandhi S, et al. PINK1-associated Parkinson's disease is caused by neuronal vulnerability to calcium-induced cell death. *Mol Cell*. 2009; 33(5):627–38. [PubMed: 19285945]
100. Rimessi A, et al. Perturbed mitochondrial Ca²⁺ signals as causes or consequences of mitophagy induction. *Autophagy*. 2013; 9(11):1677–86. [PubMed: 24121707]
101. Higa, M; , et al. Troglitazone prevents mitochondrial alterations, beta cell destruction, and diabetes in obese prediabetic rats. *Proc Natl Acad Sci U S A*; 1999. 11513–8.
102. Mizukami H, et al. Augmented β cell loss and mitochondrial abnormalities in sucrose-fed GK rats. *Virchows Archiv*. 2008; 452(4):383–392. [PubMed: 18236074]
103. Supale S, et al. Mitochondrial dysfunction in pancreatic beta cells. *Trends Endocrinol Metab*. 2012; 23(9):477–87. [PubMed: 22766318]
104. Gilon P, et al. Calcium signaling in pancreatic β -cells in health and in Type 2 diabetes. *Cell Calcium*. 2014; 56(5):340–61. [PubMed: 25239387]
105. Men X, et al. Dynamin-related protein 1 mediates high glucose induced pancreatic beta cell apoptosis. *Int J Biochem Cell Biol*. 2009; 41(4):879–90. [PubMed: 18805504]
106. Anello M, et al. Functional and morphological alterations of mitochondria in pancreatic beta cells from type 2 diabetic patients. *Diabetologia*. 2005; 48(2):282–9. [PubMed: 15654602]

107. Carraro M, Bernardi P. Measurement of membrane permeability and the mitochondrial permeability transition. *Methods Cell Biol.* 2020; 155:369–379. [PubMed: 32183968]
108. Masini M, et al. Ultrastructural alterations of pancreatic beta cells in human diabetes mellitus. *Diabetes/Metabolism Research and Reviews.* 2017; 33(6)
109. Hennings TG, et al. In Vivo Deletion of beta-Cell Drp1 Impairs Insulin Secretion Without Affecting Islet Oxygen Consumption. *Endocrinology.* 2018; 159(9):3245–3256. [PubMed: 30052866]
110. Georgiadou E, et al. Pancreatic beta cell selective deletion of mitofusins 1 and 2 (Mfn1 and Mfn2) disrupts mitochondrial architecture and abrogates glucose-stimulated insulin secretion in vivo. *bioRxiv.* 2020
111. Reinhardt F, et al. Drp1 guarding of the mitochondrial network is important for glucose-stimulated insulin secretion in pancreatic beta cells. *Biochem Biophys Res Commun.* 2016; 474(4):646–651. [PubMed: 27154223]
112. Schultz J, et al. Precise expression of Fis1 is important for glucose responsiveness of beta cells. *Journal of Endocrinology.* 2016; 230:81–91.
113. Naon D, et al. Critical reappraisal confirms that Mitofusin 2 is an endoplasmic reticulum-mitochondria tether. *Proc Natl Acad Sci U S A.* 2016; 113(40):11249–11254. [PubMed: 27647893]
114. Filadi R, et al. On the role of Mitofusin 2 in endoplasmic reticulum-mitochondria tethering. *Proc Natl Acad Sci U S A.* 2017; 114(12):E2266–e2267. [PubMed: 28289206]
115. Filadi R, et al. Mitofusin 2 ablation increases endoplasmic reticulum-mitochondria coupling. *Proceedings of the National Academy of Sciences.* 2015; 112(17):E2174–E2181.
116. Montemurro C, et al. Cell cycle-related metabolism and mitochondrial dynamics in a replication-competent pancreatic beta-cell line. *Cell Cycle.* 2017; 16(21):2086–2099. [PubMed: 28820316]
117. Kaufman BA, Li C, Soleimanpour SA. Mitochondrial regulation of β -cell function: maintaining the momentum for insulin release. *Molecular aspects of medicine.* 2015; 42:91–104. [PubMed: 25659350]
118. Copeland WC. Defects in mitochondrial DNA replication and human disease. *Crit Rev Biochem Mol Biol.* 2012; 47(1):64–74. [PubMed: 22176657]
119. Poulton J, et al. Mitochondrial DNA, diabetes and pancreatic pathology in Kearns-Sayre syndrome. *Diabetologia.* 1995; 38(7):868–71. [PubMed: 7556992]
120. Wiederkehr A, Wollheim CB. Impact of mitochondrial calcium on the coupling of metabolism to insulin secretion in the pancreatic β -cell. *Cell Calcium.* 2008; 44(1):64–76. [PubMed: 18191448]
121. Ekstrand MI, et al. Mitochondrial transcription factor A regulates mtDNA copy number in mammals. *Hum Mol Genet.* 2004; 13(9):935–44. [PubMed: 15016765]
122. Gauthier BR, et al. PDX1 deficiency causes mitochondrial dysfunction and defective insulin secretion through TFAM suppression. *Cell Metab.* 2009; 10(2):110–8. [PubMed: 19656489]
123. Nicholas L, et al. Mitochondrial transcription factor B2 is essential for mitochondrial and cellular function in pancreatic β -cells. *Molecular Metabolism.* 2017; 6:651–663. [PubMed: 28702322]
124. Koeck T, et al. A common variant in TFB1M is associated with reduced insulin secretion and increased future risk of type 2 diabetes. *Cell Metabolism.* 2011; 13:80–91. [PubMed: 21195351]
125. Butler A, et al. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. *Diabetes.* 2003; 52:102–110. [PubMed: 12502499]
126. Silva Ramos E, et al. Mitochondrial fusion is required for regulation of mitochondrial DNA replication. *PLoS genetics.* 2019; 15(6)
127. Bermont F, et al. Targeting Mitochondrial Calcium Uptake with the Natural Flavonol Kaempferol, to Promote Metabolism/Secretion Coupling in Pancreatic beta-cells. *Nutrients.* 2020; 12(2)
128. Filippin L, et al. Improved strategies for the delivery of GFP-based Ca²⁺ sensors into the mitochondrial matrix. *Cell Calcium.* 2005; 37(2):129–36. [PubMed: 15589993]
129. Berg J, Hung YP, Yellen G. A genetically encoded fluorescent reporter of ATP:ADP ratio. *Nature methods.* 2009; 6(2):161–166. [PubMed: 19122669]
130. Fex M, et al. The pathogenetic role of β -cell mitochondria in type 2 diabetes. *J Endocrinol.* 2018; 236(3):R145–r159. [PubMed: 29431147]

Highlights

- Mitochondrial Ca^{2+} uptake is essential for normal β -cell function and insulin secretion
- Changes in mitochondrial ultrastructure are observed in type 2 diabetes and may be driven by altered Ca^{2+} homeostasis.
- mtDNA mutations lead to impaired GSIS and diabetes in rodents and humans.

Figure 1. Exploring relationships between cytosolic, mitochondrial Ca^{2+} , metabolism and insulin secretion in single primary β -cells.

(A) Measurements of cytosolic Ca^{2+} (e.g. with the trappable Ca^{2+} indicator fura red), mitochondrial Ca^{2+} [128] or cytosolic ATP/ADP ratio [129] with the indicators noted are performed in perforated patch-clamped β -cells. The cell-attached Zn^{2+} sensor ZIMIR (Zinc indicator for monitoring induced exocytotic release) can be used to monitor the release of co-secreted insulin. (B) Representative trace of increases in glucose concentration over the physiological range which prompts a biphasic increase in ATP (blue) in a single β -cell. Note

the transient decrease in ATP/ADP upon the induction of action potential firing a Ca^{2+} influx (red) which gradually recovers. Current injection (arrow) provokes a further small increase in Ca^{2+} channel opening (repolarisation) and collapse upon addition of the uncoupler carbonyl cyanide-4 (trifluoromethoxy)phenylhydrazone (FCCP). Measurements were performed in 30 different β -cells. (C) Representative trace of mitochondrial Ca^{2+} uptake (green) in a single β -cell that depends on the frequency of cytosolic Ca^{2+} (red) oscillations, imposed here artificially through current injection via the patch pipette (n=13 cells in total). Adapted from [47] and [55] with permission.

Figure 2. Deletion of the MCU channel in pancreatic β -cells impairs mitochondrial Ca^{2+} uptake and insulin secretion.

(A) Each snapshot of isolated WT (i-iv) and KO-derived (v-viii) islets was taken during the time points indicated by the respective arrow in (B). Scale bars: 50 μm . (B) $[\text{Ca}^{2+}]_{\text{mito}}$ changes in response to 17mmol/l glucose (17G) (with or without diazoxide) and 20 mmol/l KCl + diazoxide were assessed in WT or KO islets following R-GECO (Ca^{2+} indicator in mitochondria) infection. Traces represent mean normalised fluorescence intensity over time (F/F_{min}). The corresponding AUC are also shown ($n = 3$ mice per genotype). (C) Insulin

secretion from islets isolated from WT and KO mice during perfusion ($n = 4-5$ mice per genotype) and **(D)** serial incubations of islets in batches, at 3 mmol/l glucose (3G) or 17 mmol/l glucose (17G) ($n = 6-7$ mice per genotype). **(E)** Blood glucose and **(F)** glucose-induced insulin secretion (intraperitoneal injection of 3 g/kg body weight of glucose) were assessed in WT and KO mice ($n = 6-9$ mice per genotype). Blue, WT mice; red, KO mice. Data are presented as mean $\pm$ SEM. * $p < 0.05$; ** $p < 0.01$; *** $p < 0.001$. Adapted from [66] with permission.

Figure 3.

Schematic representation of the metabolic cellular changes in replicating INS 832/13 cells synchronized at G1/S, S and G2/M. At G1/S the mitochondrial network is interconnected and fused which progressively fragments during the S and G2/M phases to secure mitochondrial inheritance during division. Glucose uptake and mitochondrial fusion at G1/S likely co-ordinately act to maximize ATP generation prior to the high energy requiring S and G2/M phases. While ATP levels are lowest during S phase, this suggests a high ATP consumption that physiologically occurs during DNA replication. Cytosolic and mitochondrial Ca^{2+} concentrations are elevated at the G1/S transition and further rise during G2/M to secure membrane formation during mitosis. Adapted from [116].

Figure 4.

Potential mechanisms and roles of β -cell mitochondrial dysfunction in T2D. Changes in mitochondrial structure or function in pancreatic β -cells that lead to reduced insulin secretion and T2D may be induced by several processes, alone or in combination. A number of mutations in mtDNA can cause dysfunction of mitochondria in pancreatic β -cells as can the inheritance of identified risk alleles for T2D, e.g. *TFB1M* that is required for translation of proteins in mitochondria. Chronic metabolic changes such as elevations of circulating lipids and/or glucose, known as lipo- and glucotoxicity, respectively, may also interact with gene variants and affect negatively mitochondrial function in β -cells. Mitochondrial dysfunction can be reflected by an impairment in Ca^{2+} uptake, bioenergetics and ATP production, as well as in biogenesis and apoptosis. These processes may impair the production and release of insulin and may potentially lead to mitochondrial fragmentation and β -cell death. Adapted from [130].